Advanced Search

Virginia Mason Community Clinical Oncology Program		E-Mail this page Define terms on this page
Principal Investigator:	Jacobs, Andrew D
Institution:	Benaroya Research Inst at Virginia Mason
State:	WA
NCI Program Director:	Kelaghan, Joseph	View related clinical trials conducted by this group
NCI Division:	Division of Cancer Prevention
Project ID:	U10, CA035192
Project Funding Period:	6/01/00 to 5/31/05

The broad objectives and specific aims of the Virginia Mason CCOP are as follows: 1) To increase accrual to CCOP treatment by seven patients per year, achieving a total of 100 patients per year by 2002. 2) To increase accrual to Cancer Control and Prevention Trials protocols with a similar goal of 100 patients per year by 2002. Achievement of this goal will depend in part on the availability of major cancer prevention trials to replace the Breast Cancer Prevention Trial and Prostate Cancer Prevention Trial when accural to these trials is completed. 3) To bring the advantages of state-of-the-art cancer treatment and cancer control trials to patients in metropolitan Seattle and in smaller communities in western Washington and Alaska by strengthening and expanding both the core institution participation in the activities of the CCOP and our relationship with the component institutions, Valley Medical Center (Renton, Washington), Evergreen Medical Center (Kirtland, Washington), Olympic Memorial Hospital (Port Angeles, Washington), Providence Medical Center (Anchorage, Alaska), the North Idaho Cancer Center (Coeur d'Alene, Idaho), and the physicians who practice in these hospitals. 4) To seek out and develop relationships with other medical institutions in the Pacific Northwest and Alaska, hoping to expand the number of component institutions committed to the goals and directions of the VM CCOP. An initial priority is to incorporate Group Health Cooperative of Puget Sound into the VM CCOP. 5) To seek ways of increasing involvement of minorities and women in cancer trials, particularly Cancer Control and Prevention Trials by reaching out to the African-American and Asian communities in Seattle.

 
Related Clinical Trials Conducted by the group:

1	Phase I Pilot Study of Gefitinib in Patients Age 75 and Over or Age 50 and Under With Metastatic or Unresectable Carcinoma of the Head and Neck or Non-Small Cell Lung Cancer
2	Phase I Study of EGFRvIII Peptide Vaccine With Sargramostim (GM-CSF) Versus Keyhole Limpet Hemocyanin as Adjuvant in Patients With EGFRvIII-Expressing Cancer
3	Phase II Pilot Study of Docetaxel, Cisplatin, and Fluorouracil Followed By Accelerated Fractionation/Concomitant Boost Radiotherapy and Concurrent Cisplatin in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck
4	Phase II Pilot Study of Rituximab and Alternating Chemotherapy Regimens in Patients With Previously Untreated Mantle Cell Lymphoma
5	Phase II Pilot Study of Trastuzumab (Herceptin), Docetaxel, and Vinorelbine With Filgrastim (G-CSF) Support in Women With HER2-Positive Stage IV Breast Cancer
6	Phase II Randomized Study of Celecoxib in Premenopausal Women at High Risk for Developing Breast Cancer
7	Phase II Randomized Study of Concurrent Versus Sequential Paclitaxel, Carboplatin, and Cetuximab in Patients With Selected Stage IIIB or Stage IV Non-Small Cell Lung Cancer
8	Phase II Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab With or Without Epratuzumab in Patients Age 60 and Over With Previously Untreated Stage III or IV or Bulky Stage II Diffuse Large B-Cell Non-Hodgkin's Lymphoma
9	Phase II Randomized Study of Imatinib Mesylate at Standard Versus Increased Dose Alone Versus Imatinib Mesylate and Cytarabine Versus Imatinib Mesylate and PEG-Interferon alfa-2a in Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
10	Phase II Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
11	Phase II Study of Adjuvant Chemoradiotherapy Comprising Cisplatin and Docetaxel After Complete Resection in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck
12	Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation With Pre-Conditioning Low-Dose Total Body Irradiation and Fludarabine Followed By Mycophenolate Mofetil and Cyclosporine in Elderly Patients With Acute Myeloid Leukemia in First Complete Remission
13	Phase II Study of Arsenic Trioxide in Men With Refractory Testicular or Extragonadal Germ Cell Malignancies
14	Phase II Study of Bevacizumab in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
15	Phase II Study of Bortezomib in Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Therapy
16	Phase II Study of Capecitabine in Elderly Patients With Unresectable Metastatic or Recurrent Colorectal Cancer
17	Phase II Study of Complete Surgical Resection in Patients With Stage IV Melanoma
18	Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone and Radiotherapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Aggressive Stage I or IE or Non-Bulky Stage II or IIE CD20-Positive Non-Hodgkin's Lymphoma
19	Phase II Study of Docetaxel in Elderly Women With Metastatic Breast Cancer
20	Phase II Study of Docetaxel in Patients With Locally Advanced or Metastatic Epidermoid Carcinoma of the Penis
21	Phase II Study of Early Estramustine, Etoposide, and Paclitaxel With Combined Androgen Blockade Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate
22	Phase II Study of Erlotinib in Patients With Advanced Primary Non-Small Cell Lung Cancer and a Zubrod Performance Status of 2
23	Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
24	Phase II Study of Erlotinib in Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
25	Phase II Study of FR901228 in Patients With Advanced Transitional Cell Carcinoma of the Urothelium That Has Progressed After Prior Chemotherapy
26	Phase II Study of FR901228 in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
27	Phase II Study of GVAX Lung Cancer Vaccine in Patients With Selected Stage IIIB or Stage IV Bronchoalveolar Carcinoma
28	Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer
29	Phase II Study of Gemcitabine and Paclitaxel in Patients With Advanced or Recurrent Urothelial Cancer
30	Phase II Study of Gemcitabine, Carboplatin, and Bortezomib in Patients With Chemotherapy-Na??A?ve Advanced or Recurrent Non-Small Cell Lung Cancer
31	Phase II Study of Gemtuzumab Ozogamicin and Cytarabine in Patients With Relapsed Acute Myeloid Leukemia
32	Phase II Study of High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Multiple Myeloma or Primary Systemic Amyloidosis
33	Phase II Study of Hydroxyurea in Patients With Unresectable Benign Meningioma
34	Phase II Study of Imatinib Mesylate and Capecitabine in Women With Progressive Stage IV Adenocarcinoma of the Breast
35	Phase II Study of Imatinib Mesylate in Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (DFSP) or Transformed Fibrosarcomatous DFSP
36	Phase II Study of Imatinib Mesylate in Patients With Metastatic or Unresectable Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
37	Phase II Study of Imatinib Mesylate in Patients With Platinum- and Taxane-Refractory Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer
38	Phase II Study of Induction Tirapazamine, Cisplatin, and Etoposide With Concurrent Thoracic Radiotherapy Followed By Consolidation Cisplatin and Etoposide in Patients With Limited Stage Small Cell Lung Cancer
39	Phase II Study of Irinotecan in Patients With Recurrent or Refractory Advanced Transitional Cell Carcinoma of the Urothelium Previously Treated With Platinum-Based Chemotherapy
40	Phase II Study of Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed By Concurrent Cisplatin and Radiotherapy in Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
41	Phase II Study of Neoadjuvant Gemcitabine, Paclitaxel, and Carboplatin Followed By Observation or Immediate Cystectomy in Patients With Stage II or III Transitional Cell Cancer of the Urothelium
42	Phase II Study of Neoadjuvant Oxaliplatin, Fluorouracil, and Radiotherapy Followed By Definitive Surgical Resection in Patients With Stage II or III Squamous Cell Carcinoma or Adenocarcinoma of the Esophagus or Gastroesophageal Junction
43	Phase II Study of Neoadjuvant Paclitaxel and Carboplatin Followed By Surgery and Adjuvant Paclitaxel and Carboplatin in Patients With Stage III or IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
44	Phase II Study of Paclitaxel, Cisplatin, and Doxorubicin HCl Liposome in Patients With Optimally Debulked Stage III Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
45	Phase II Study of Surgery and Ad5CMV-p53 Gene Followed By Cisplatin and Radiotherapy in Patients With Newly Diagnosed Resectable Stage III or IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
46	Phase II Study of Targeted Induction Chemotherapy Followed By Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Rectum
47	Phase II Study of Thalidomide and Dexamethasone Induction Followed By Tandem Melphalan and Peripheral Blood Stem Cell Transplantation Followed By Prednisone and Thalidomide Maintenance in Patients With Multiple Myeloma
48	Phase II/III Randomized Study of Ginger for Chemotherapy-Related Nausea in Patients With Cancer
49	Phase III Randomized Chemoprevention Study of Celecoxib in Patients With Resected Stage I Adenocarcinoma of the Colon
50	Phase III Randomized Study of Adjuvant Androgen Deprivation Therapy With or Without Mitoxantrone and Prednisone After Radical Prostatectomy in Patients With High-Risk Adenocarcinoma of the Prostate
51	Phase III Randomized Study of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide With or Without Celecoxib Versus Doxorubicin and Cyclophosphamide With or Without Celecoxib in Women With Node-Negative Breast Cancer
52	Phase III Randomized Study of Anastrozole Versus Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ of the Breast Undergoing Lumpectomy and Radiotherapy
53	Phase III Randomized Study of Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
54	Phase III Randomized Study of Carboplatin With or Without Pegylated Doxorubicin HCl Liposome in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
55	Phase III Randomized Study of Cisplatin and Irinotecan Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer
56	Phase III Randomized Study of Cisplatin, Etoposide, Radiotherapy, and Docetaxel With or Without Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
57	Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Either Rituximab or Iodine I 131 Tositumomab (Monoclonal Antibody Anti-B1) in Patients With Newly Diagnosed Follicular Non-Hodgkin's Lymphoma
58	Phase III Randomized Study of Dexamethasone With or Without CC-5013 in Patients With Newly Diagnosed Multiple Myeloma
59	Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin) in Women With Node-Positive Breast Cancer That Overexpresses HER2
60	Phase III Randomized Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin Versus Capecitabine and Oxaliplatin With or Without Bevacizumab in Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
61	Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer
62	Phase III Randomized Study of Gemcitabine With Versus Without Cetuximab as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas
63	Phase III Randomized Study of Gemcitabine With or Without Dalteparin in Patients With Unresectable or Metastatic Pancreatic Cancer
64	Phase III Randomized Study of Goserelin for the Reduction of Premature Ovarian Failure in Women With Stage I-IIIA Hormone Receptor-Negative Breast Cancer Undergoing Adjuvant Chemotherapy
65	Phase III Randomized Study of Induction Therapy Comprising Cytarabine and Daunorubicin With Versus Without Gemtuzumab Ozogamicin Followed By Consolidation Therapy Comprising High-Dose Cytarabine and Post-Consolidation Therapy Comprising Gemtuzumab Ozogamicin Versus No Additional Therapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia
66	Phase III Randomized Study of Interferon alfa Versus Cisplatin, Vinblastine, and Dacarbazine Plus Interferon alfa and Interleukin-2 in Patients With High-Risk Melanoma
67	Phase III Randomized Study of Interleukin-2 Versus Observation Only After Total Body Irradiation, High-Dose Etoposide, Cyclophosphamide, and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Adult Non-Hodgkin's Lymphoma
68	Phase III Randomized Study of Intermittent Versus Continuous Combined Androgen-Deprivation Therapy Comprising Bicalutamide and Goserelin in Patients With Metastatic Stage IV Prostate Cancer Responsive to Such Therapy
69	Phase III Randomized Study of L-Glutamine For Radiotherapy-Induced Oral Mucositis in Patients With Newly Diagnosed, Previously Untreated Squamous Cell Cancer of the Oral Cavity or Oropharynx Receiving High-Dose Radiotherapy
70	Phase III Randomized Study of Medroxyprogesterone Acetate Versus Observation for Prevention of Endometrial Pathology in Postmenopausal Women With Breast Cancer Treated With Adjuvant Tamoxifen
71	Phase III Randomized Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Observation Alone Based on p53 Gene Status in Patients With Organ Confined Transitional Cell Carcinoma of the Bladder Who Have Undergone Radical Cystectomy and Bilateral Pelvic Lymphadenectomy
72	Phase III Randomized Study of Modafinil for Fatigue in Cancer Patients Receiving Chemotherapy
73	Phase III Randomized Study of Octreotide Versus Standard Care for Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer
74	Phase III Randomized Study of Preoperative Capecitabine and Radiotherapy Versus Fluorouracil and Radiotherapy in Patients With Resectable Rectal Cancer
75	Phase III Randomized Study of Radiotherapy and Carmustine With or Without O6-Benzylguanine in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
76	Phase III Randomized Study of Selenium as Chemoprevention of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia
77	Phase III Randomized Study of Standard Neoadjuvant Doxorubicin and Cyclophosphamide Followed By Weekly Paclitaxel Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide With Filgrastim (G-CSF) Followed By Weekly Paclitaxel in Women With Inflammatory or Locally Advanced Breast Cancer
78	Phase III Randomized Study of Surgery With or Without Preoperative Paclitaxel and Carboplatin in Patients With Stage IB, II, or Selected IIIA Non-Small Cell Lung Cancer
79	Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma
80	Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
81	Randomized Study of Co-Trimoxazole Versus Ciprofloxacin or Ofloxacin Versus No Prophylaxis for the Prevention of Early Infection in Patients With Multiple Myeloma
82	Study of Multicolor Fluorescence Immunocytochemistry and Bright Field Immunocytochemistry for the Detection of Tumor Cells in Bone Marrow of Women With Stage I, II, or IIIA Breast Cancer Undergoing Surgery
83	Supportive-Expressive Group Therapy for Men with Stage I/II Prostate Cancer

This project is coded as follows:

Type of Cancer Research Codes:

• Education and Communication
• Resources and Infrastructure Related to Cancer Control, Survivorship, and Outcomes Research

Type of Cancer Codes:

• Bladder Cancer
• Blood Cancer
• Bone Marrow Transplantation
• Brain Tumor
• Breast Cancer
• Cervical Cancer
• Colon and Rectal Cancer
• Esophageal Cancer
• Gastrointestinal Tract
• Genital System, Female
• Genital System, Male
• Head and Neck Cancer
• Leukemia
• Lung Cancer
• Melanoma
• Myeloma
• Nervous System
• Non-Hodgkin's Lymphoma
• Not Site-Specific Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Respiratory System
• Skin Cancer
• Stomach Cancer
• Testicular Cancer
• Urinary System

Research Portfolio Home | Dictionary | Site Map | Privacy Policy | Accessibility | Contact Us